
Precipio: A leading cancer diagnostics lab, providing expert advice for optimal patient care.
Founded with a mission to revolutionize cancer diagnostics, Precipio aims to provide the most accurate and efficient diagnostic advice to enhance patient care. The company offers proprietary hematology diagnostic products, including Bloodhound™ and HemeScreen® molecular kits, which detect various mutations related to blood cancers like MPN, CLL, and AML. Precipio focuses on improving laboratory throughput and economics while ensuring superior diagnostic accuracy for patients and physicians.
Precipio has garnered attention for its innovative approach to cancer diagnostics, attracting notable investors and partnerships within the medical and biotech sectors. The company's achievements include the development of advanced diagnostic tools that significantly enhance the speed and accuracy of hematology testing. By prioritizing precision and efficiency, Precipio has made a substantial impact on the quality of cancer diagnostics, ultimately contributing to better patient outcomes.

Torpedo Diagnostics

Foundation Medicine

Accelerated Medical Diagnostics

Exact Sciences
exactsciences.com

Predictive Health Diagnostics Company

Cleveland Diagnostics
clevelanddx.com

Empowered Diagnostics

CDx Diagnostics

Guardant Health
guardanthealth.com

Avant Diagnostics

Acuamark Diagnostics
acuamarkdx.com

Prompt Diagnostics
prompt-dx.com

Oncocyte
oncocyte.com

Castle Biosciences

Eventus Diagnostics
Companies similar to Precipio include Torpedo Diagnostics, Foundation Medicine, Accelerated Medical Diagnostics and Exact Sciences.
Precipio was founded in 2011.
Precipio's headquarters is located in New Haven, CT, US.
Precipio's most recent funding round was for $400k (USD) in July 2017.
As of Jul 14, 2017, Precipio has raised a total of $3.3M (USD).
Precipio has 68 employees as of Feb 6, 2024.